最新刊期

      WANG Tingting, MA Yizhong, WANG Yujie, WANG Siyu, WANG Yifeng, HAN Xianghui, WANG Jianyi

      DOI：10.16305/j.1007-1334.2026.z20260120004
      摘要：ObjectiveTo evaluate the clinical efficacy and safety of adding Rougan Sanjie Formula to tenofovir alafenamide (TAF) in treating patients with compensated hepatitis B-related cirrhosis presenting a latent pathogen and blood stasis syndrome.MethodsSeventy-five patients diagnosed with compensated HBV-related liver cirrhosis and differentiated as latent pathogen and blood stasis syndrome were randomly assigned to either the treatment group (n=38) or the control group (n=37). The treatment group received Rougan Sanjie Formula plus TAF, whereas the control group received a mimicked placebo Rougan Sanjie Formula plus TAF. Both interventions lasted 24 weeks. Liver stiffness measurement (LSM), TCM syndrome scores and efficacy, biochemical parameters, and safety outcomes were compared between groups.Results①A total of 72 patients completed the full treatment and efficacy evaluation, including 36 in each group. ②LSM decreased significantly after treatment in both groups (P<0.05); post-treatment LSM was lower in the treatment group than that in the control group (P<0.05). ③Post-treatment TCM syndrome scores in the treatment group were significantly lower than those in the control group (P<0.05). The difference in TCM syndrome efficacy between the two groups was statistically significant, and the treatment group showed superior efficacy to the control group (P<0.05). ④Serum ALT, AST, GGT and TBil decreased significantly after treatment in both groups (P<0.05); the treatment group had lower post-treatment GGT than the control group (P<0.05). ⑤Serum LN decreased in the treatment group and Ⅳ-C decreased in the control group after treatment (P<0.05); the treatment group had lower post-treatment LN than the control group (P<0.05). ⑥No obvious adverse events or abnormal safety parameters occurred during the trial.ConclusionRougan Sanjie Formula combined with TAF shows favorable efficacy and safety in compensated HBV-related liver cirrhosis with latent pathogen and blood stasis syndrome, and can significantly improve clinical indicators and TCM syndrome manifestations.  
      关键词：hepatitis B;liver cirrhosis;liver fibrosis;Rougan Sanjie Formula;syndrome differentiation and treatment;integrated traditional Chinese and western medicine;clinical trial   
      9
      |
      0
      |
      0
      <HTML>
      <L-PDF>
      <引用本文> <批量引用> 154182188 false
      更新时间：2026-04-11

      CHEN Hao, LUO Lei, LIU Shan, WANG Ao, ZHONG Yifei, LI Yi

      DOI：10.16305/j.1007-1334.2026.z20251211003
      摘要：ObjectiveTo investigate the mechanism of moxibustion intervention on renal tubulointerstitial fibrosis (TIF) in mice with unilateral ureteral obstruction (UUO).MethodsA TIF mouse model was established using the UUO method in C57BL/6J mice. The mice were divided into Sham operation (Sham) group, Sham operation plus moxibustion (Sham+Moxa) group, Model group, and Model plus moxibustion (Moxa) group. Pathological changes in renal tissue were observed using Hematoxylin-Eosin, Sirius Red and Masson's staining. Collagen volume fraction (CVF) was measured, and immunohistochemistry was performed to detect α-smooth muscle actin (α-SMA), type Ⅰ collagen (Col Ⅰ), so as to evaluate the degree of TIF. The immunofluorescence method was used to detect hypoxia-inducible factor-1α (HIF-1α) in renal tubules to assess the ischemic-hypoxic state of renal tubules; Platelet reaction protein 1 (TSP-1) and platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) were detected to evaluate vascular injury; Double staining with the anti-aging protein Klotho/CD31 was detected to assess the Klotho expression in the endothelial cells of peritubular capillaries (PTC) around the renal tubules. Real-time fluorescence quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to measure the mRNA expression of fibrosis-related factors Snail family transcriptional repressor 1 (Snail1) and CCAAT enhancer binding protein delta (Cebpd).ResultsMoxibustion could significantly improve renal tubular atrophy and luminal stenosis, reduce extracellular matrix hyperplasia and interstitial collagen fiber expression, and decrease CVF. Immunohistochemistry showed that moxibustion could reduce the positive expression of α-SMA and Col I in the renal tubulointerstitium. Immunofluorescence revealed that moxibustion could decrease the positive expression of HIF-1α and TSP-1 in renal tubular epithelial cells and increase the positive expression of CD31 and Klotho in PTC endothelial cells. RT-qPCR demonstrated that moxibustion could downregulate the mRNA expression of Snail1 and Cebpd in renal tissue.ConclusionsMoxibustion delays the progression of TIF by upregulating Klotho expression in PTC endothelial cells, alleviating ischemia and hypoxia in renal tubular epithelial cells, and inhibiting the expression of fibrosis-related factors.  
      关键词：tubulointerstitial fibrosis;chronic kidney disease;moxibustion;endothelial cells;traditional Chinese medicine therapies;mechanism of action   
      5
      |
      0
      |
      0
      <HTML>
      <L-PDF>
      <引用本文> <批量引用> 154021069 false
      更新时间：2026-04-08
    0